PDCD1 and hepatocellular carcinoma: A clinical trial in China (NCT02989922) involving 220 patients with progressive HCC from 13 centers showed a similar treatment efficacy for camrelizumab and other PD-1 monoclonal antibodies, with an objective response rate of 14.7%, 6-month survival rate of 74.4%, and median OS time of 13.8 months (5).